Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone | Zendy

Yaacov Ori | Zendy; A Chagnac | Zendy; Asher Korzets | Zendy; Boris Zingerman | Zendy; Michal HermanEdelstein | Zendy; Michael Bergman | Zendy; Uzi Gafter | Zendy; H. Salman | Zendy

Open Access

Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone

Author(s) -

Yaacov Ori,

A Chagnac,

Asher Korzets,

Boris Zingerman,

Michal HermanEdelstein,

Michael Bergman,

Uzi Gafter,

H. Salman

Publication year - 2013

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfs587

Subject(s) - medicine , left ventricular hypertrophy , primary aldosteronism , spironolactone , cardiology , mineralocorticoid receptor , aldosterone , incidence (geometry) , essential hypertension , mineralocorticoid , renin–angiotensin system , endocrinology , blood pressure , physics , optics

The incidence of left ventricular hypertrophy (LVH) in primary aldosteronism (PA) is higher than in essential hypertension. LVH is an independent cardiovascular risk factor. Treatment of PA with mineralocorticoid receptor blockers (MRBs) improves LVH. Previous studies included relatively small groups, low incidence of LVH and used high MRB dose. We tested the hypothesis that long-term regression of LVH in PA/low-renin hypertension may be achieved with low-dose MRB.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research